Factors predicting cardiovascular events in statin-treated diabetic and non-diabetic patients with coronary

Related Experiment Videos

Heinz Drexel1, Stefan Aczel, Thomas Marte

  • 1Vorarlberg Institute for Vascular Investigation and Treatment, Academic Teaching Hospital Feldkirch, Carinagasse 47, A-6807 Feldkirch, Austria. vivit@lkhf.at

Atherosclerosis
|September 15, 2009
PubMed

Insights

In statin-treated patients with coronary artery disease, low high-density lipoprotein (HDL) cholesterol and high triglycerides are key drivers of vascular risk. This pattern is particularly pronounced in patients with type 2 diabetes.

Area of Science:

  • Cardiovascular Medicine
  • Lipidology
  • Metabolic Syndrome

Background:

  • Coronary artery disease (CAD) patients on statin therapy remain at significant vascular risk.
  • Identifying specific lipid factors influencing this risk is crucial for optimizing treatment strategies.

Purpose of the Study:

  • To determine which lipid parameters predict vascular events in statin-treated patients with stable CAD.
  • To investigate the role of HDL- and LDL-related factors in vascular risk within this population.

Main Methods:

  • Prospective recording of vascular events over 5.6 years in 491 statin-treated CAD patients.
  • Analysis of lipid profiles, including high-density lipoprotein (HDL) cholesterol, apolipoprotein A1, low-density lipoprotein (LDL) particle size, and triglycerides.
  • Factor analysis to identify HDL- and LDL-related lipid components.

Main Results:

  • Low HDL cholesterol, low apolipoprotein A1, small LDL particle diameter, and high triglycerides were significant predictors of vascular events.
  • An HDL-related factor, but not an LDL-related factor, independently predicted vascular events.
  • Patients with type 2 diabetes (T2DM) exhibited higher vascular risk, with the HDL-related factor remaining a significant predictor.

Conclusions:

  • The lipid profile characterized by low HDL cholesterol, low apolipoprotein A1, small LDL particles, and high triglycerides is a primary driver of vascular risk in statin-treated CAD patients.
  • These findings are particularly relevant for managing vascular risk in diabetic CAD patients.
  • Targeting HDL-related lipid factors may offer therapeutic benefits in this high-risk population.
Abstract

Related Concept Videos

Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
Factors Affecting Protein-Drug Binding: Patient-Related Factors01:29

Factors Affecting Protein-Drug Binding: Patient-Related Factors

Protein-drug binding, a pivotal aspect of pharmacokinetics, is subject to considerable variability influenced by an array of patient-related factors. The intricate interplay of age, individual differences, and pathological conditions significantly impact the binding dynamics and subsequent pharmacological effects.
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...